Diabetes drug trial aims to halt brain disease linked to stroke and dementia
NCT ID NCT05356104
Summary
This study is testing if a medication commonly used for diabetes (a GLP-1 agonist) can safely slow down or prevent the worsening of cerebral small vessel disease (cSVD), a condition that damages tiny blood vessels in the brain and can lead to stroke, dementia, and walking problems. The 78-week pilot study will involve 110 participants aged 55-80 who already have moderate-to-severe signs of the disease on brain scans. Half will receive the study drug plus standard care, while the other half receives standard care alone, to see if the drug improves brain health, thinking skills, and mobility.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL SMALL VESSEL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.